Abstract
Notes
Ethics Statement
This study was exempted from the review by the institutional ethics committee. This article does not include any information that may identify the person.
Author Contributions
Concept and design: SHB, JYK, and CJ. Analysis and interpretation: SHB, JYK, and CJ. Data collection: SHB, JYK, and CJ. Writing the article: SHB. Critical revision of the article: SHB and CJ. Final approval of the article: SHB, JYK, and CJ, Statistical analysis: SHB. Overall responsibility: SHB, JYK, and CJ.
REFERENCES
Table 1.
Characteristic | BEST [14] | BASICS [15] | BAOCHE [16] | ATTENTION [17] | |
---|---|---|---|---|---|
Publication year (study duration) | 2020 (2015–2017) | 2021 (2011–2019) | 2022 (2016–2021) | 2022 (2021–2022) | |
Countries | China | 7 countries | China | China | |
Inclusion criteria | |||||
Age (y) | ≥18 | Initially18–85 (extended later to ≥18) | 18–80 | ≥18 | |
Pre-stroke mRS | 0–2 | 0–2 | 0–1 | Age ≤80, 0–2 | |
Age >80, 0 | |||||
Time window | Within 8 hours | Within 6 hours | 6–24 hours | Within 12 hours | |
Clinical severity | None | Initially ≥10 (extended later to include NIHSS <10) | Initially ≥10 (extended to include NIHSS ≥6 | NIHSS ≥10 | |
Imaging-based | None | None | PC-ASPECTS ≥6 and pons-midbrain index ≤2 | Age <80, PC-ASPECTS ≥6 | |
Age ≥80, PC-ASPECTS ≥8 | |||||
Exclusion-imaging based | ICH, significant cerebellar mass effect, acute hydrocephalus, or extensive bilateral brainstem ischemia | ICH, extensive bilateral brainstem infarction; cerebellar mass effect; or acute hydrocephalus | Complete bilateral thalami or brainstem infarction | ||
Crossover rates (%) | |||||
EVT to BMM | 5 | 1.9 | 0.9 | 1.3 | |
BMM to EVT | 22 | 4.8 | 3.7 | 2.6 |
BEST, Basilar Artery Occlusion Endovascular Intervention Versus Standard Medical Treatment; BASICS, Basilar Artery International Cooperation Study; BAOCHE, Basilar Artery Occlusion Chinese Endovascular; ATTENTION, Endovascular Treatment for Acute Basilar Artery Occlusion; mRS, modified Rankin scale; NIHSS, National Institutes of Health Stroke Scale; PC-ASPECTS, Posterior Circulation Acute Stroke Prognosis Early Computed Tomography Score; ICH, intracranial hemorrhage; EVT, endovascular treatment; BMM, best medical management.
Table 2.
Characteristic |
BEST [14] |
BASICS [15] |
BAOCHE [16] |
ATTENTION [17] |
||||
---|---|---|---|---|---|---|---|---|
EVT | Control | EVT | Control | EVT | Control | EVT | Control | |
Patients | 66 | 65 | 154 | 146 | 110 | 107 | 226 | 114 |
Age (y) | 62 (50–74) | 68 (57–74) | 66.8±13.1 | 67.2±11.9 | 64.2±9.6 | 63.7±9.8 | 66.0±11.1 | 67.3±10.2 |
Male sex | 48 (73) | 52 (80) | 100 (64.9) | 96 (65.8) | 80 (73) | 79 (74) | 149 (66) | 82 (72) |
Median NIHSS score | 32 (18–38) | 26 (13–37) | 21 | 22 | 20 (15–29) | 19 (12–30) | 24 (15–35) | 24 (14–35) |
Median PC-ASPECTS | 8 (7–9) | 8 (7–9) | NA | NA | 8 (7–10) | 8 (7–10) | 9 (8–10) | 10 (8–10) |
Atrial fibrillation | 18 (27) | 10 (15) | 44 (29) | 22 (15) | 14 (13) | 13 (12) | NA | NA |
Cardioembolism | 14 (21) | 17 (26) | 51 (34.9) | 24 (18.2) | 11 (10.0) | 7 (6.5) | 46 (20) | 26 (23) |
Large-artery atherosclerosis | 37 (56) | 32 (49) | 53 (36.3) | 43 (32.6) | 75 (68.2) | 69 (64.5) | 108 (48) | 42 (37) |
IV thrombolysis | 18 (27) | 21 (32) | 121 (79) | 116 (80) | 15 (14) | 23 (21) | 69 (31) | 39 (34) |
Stroke onset to randomization | 246 (139–360) | 278 (191–387) | NA | NA | 664 (512–861) | 662 (492–838) | 306 (222–432) | 294 (210–420) |
Stroke onset to groin puncture | NA | NA | 264 (198–372) | NA | NA | NA | 336 (210–450) | NA |
Stroke onset to revascularization | 400 (269–526) | 418 (329−510) | NA | NA | 790 (626–1,000) | NA | 414 (300–528) | NA |
mTICI score 2b or 3 | 45 (71) | NA | 63 (72) | NA | 89 (88) | NA | 208 (93) | NA |
mRS score 0–2 at 90 days | 22 (33) | 18 (28) | 54 (35) | 44 (30) | 43 (39) | 15 (14) | 75 (33) | 12 (11) |
mRS score 0–3 at 90 days | 28 (42) | 21 (32) | 68 (44) | 55 (38) | 51 (46) | 26 (24) | 104 (46) | 26 (23) |
Procedure related complications | NA | 5 (3) | 12 (11) | 32 (14) | ||||
Death within 90 days | 22 (33) | 25 (38) | 59 (38) | 63 (43) | 34 (31) | 45 (42) | 83 (37) | 63 (55) |
Symptomatic ICH | 5 (8) | 0 | 7 (5) | 1 (1) | 9/102 | 2/88 | 12 (5) | 0 |
Values are presented as number only, median (interquartile range), mean±standard deviation, or number (%).
BEST, Basilar Artery Occlusion Endovascular Intervention Versus Standard Medical Treatment; BASICS, Basilar Artery International Cooperation Study; BAOCHE, Basilar Artery Occlusion Chinese Endovascular; ATTENTION, Endovascular Treatment for Acute Basilar Artery Occlusion; EVT, endovascular treatment; NIHSS, National Institutes of Health Stroke Scale; PC-ASPECTS, Posterior Circulation Acute Stroke Prognosis Early Computed Tomography Score; NA, not available; IV, intra-venous; mTICI, modified thrombolysis in cerebral infarction scale; mRS, modified Rankin scale; ICH, intracranial hemorrhage.
Table 3.
First author year | Study type | Number | NIHSS | IV tPA (%) | Technique (%) | Procedure time* (min) | Angiographic outcome (%) | Clinical outcome† (%) | sICH (%) |
---|---|---|---|---|---|---|---|---|---|
Gao 2015 [47] | Single center | 13 | 26±4 | 0 | SR: 100 | 93 | mTICI 2b–3: 100 | mRS 0–2: 46.2 | 0 |
Retrospective | Angioplasty: 100 | Mortality: 0 | |||||||
Infusion tirofiban: 46.2 | |||||||||
Kim 2016 [40] | Single center | 19 | 14 (6–23) | 21.1 | SR: 21.1 | 96 | mTICI 2b–3: 89.5 | mRS 0–2: 10.5 | NA |
Retrospective | CA: 78.9 | Mortality: 26.3 | |||||||
Angioplasty: 31.6 | |||||||||
Lee 2018 [41] | Two centers | 92 | 12 (6–24) | 13 | SR: 70.7 | 87 | mTICI 2b–3: 55.4 | mRS 0–2: 35.8 | NA |
Retrospective | Angioplasty: 31.5 | ||||||||
Piechowiak 2020 [44] | Single center | 14 | NA | NA | Balloon angioplasty: 57 | 114 | mTICI 2b–3: 92.9 | mRS 0–2: 30.8 | NA |
Retrospective | Stenting: 28 | Mortality: 38.5 | |||||||
Baik 2019 [23] | Single center | 20 | 13 (7–22) | 25 | SR: 60 | 63 | mTICI 2b–3: 55 | mRS 0–2: 20 | 10 |
Retrospective | CA: 30 | ||||||||
Angioplasty: 35 | |||||||||
Baek 2019 [45] | Single center | 24 | 14 (9–21) | 41.7 | SR: 73.3 | 45 | mTICI 2b–3: 79.2 | mRS 0–2: 37.5 | 12.5 |
Retrospective | CA: 20 | Mortality: 16.7 | |||||||
IA thrombolysis: 6.7 | |||||||||
Berndt 2020 [46] | Single center | 31 | 18 (10–23) | 38.7 | Successful aspiration: 29 | 125 | mTICI 2b–3: 87.1 | mRS 0–3: 16.1 | NA |
Retrospective | Permanent stent: 84 | mTICI 3: 64.5 | |||||||
Sun 2021 [49] | Single center | 116 | 21 (10–34) | 19.8 | Stent retriever: 69 | 90 | mTICI 2b–3: 86.2 | mRS 0–2: 36.2 | 4.3 |
Retrospective | Infusion tirofiban: 76.7 | mTICI 3: 66.4 | mRS 0–3: 52.6 | ||||||
Balloon angioplasty: 24 | Mortality: 17.2 | ||||||||
Stenting: 72 | |||||||||
Jiang 2021 [48] | Single center | 36 | 20.6±9.6 | SR: 38.1 | 122 | mTICI 2b–3: 94 | mRS 0–3: 56 | 8 | |
Retrospective | CA: 0 | Mortality: 19 | |||||||
Angioplasty: 25 | |||||||||
Kwon 2022 [43] | Single center | 36 | 13 (7–22) | 27.8 | SR: 38.1 | 72 | mTICI 2b–3: 92.5 | mRS 0–2: 33.3 | 0 |
Retrospective | CA: 14.3 | mTICI 3: 57.1 | Mortality: 14.3 | ||||||
Balloon angioplasty: 81 | |||||||||
Stenting: 61.9 | |||||||||
Pirson 2022 [24] | MR CLEAN | 84 | 17 (10–29) | 44 | SR: 56 | 64 | NA | mRS 0–2: 23 | NA |
Retrospective | CA: 34 | ||||||||
Stenting: 18 |
Values are presented as mean±standard deviation or median (interquartile range).
NIHSS, National Institutes of Health Stroke Scale; IV, intra-venous; tPA, tissue plasminogen activator; sICH, symptomatic intracranial hemorrhage; SR, stent retriever; mTICI, modified thrombolysis in cerebral infarction scale; mRS, modified Rankin scale; CA, contact aspiration; IA, intra-arterial; NA, not available; MR CLEAN, multicenter randomized clinical trial of endovascular treatment for acute ischemic stroke in the Netherlands.
Table 4.
First author year | Study type | Number | NIHSS | IV tPA (%) | Technique (%) | Procedure time* (min) | Angiographic outcome (%) | Clinical outcome† (%) | sICH (%) |
---|---|---|---|---|---|---|---|---|---|
Kim 2016 [40] | Single center | 32 | 22 (14–26) | 62.5 | SR: 15.6 | 61 | mTICI 2b–3: 87.5 | mRS 0–2: 37.5 | NA |
Retrospective | CA: 84.4 | mRS 0–3: 56.2 | |||||||
Angioplasty: 12.5 | Mortality: 21.9 | ||||||||
Lee 2018 [41] | Two centers | 102 | 19 (9–26) | 39.2 | SR: 75.5 | 63 | mTICI 2b–3: 84.3 | mRS 0–2: 52.9 | NA |
Retrospective | Angioplasty: 4.9 | ||||||||
Siebert 2019 [56] | Two centers | 116 | 12 (8–22) | 47.4 | NA | 49 | mTICI 2b–3: 83.7 | mRS 0–2: 24.2 | NA |
Retrospective | |||||||||
Piechowiak 2020 [44] | Single center | 23 | NA | NA | NA | 72 | mTICI 2b–3: 95.7 | mRS 0–2: 23.8 | NA |
Retrospective | Mortality: 47.6 | ||||||||
Baik 2019 [23] | Single center | 34 | 11 (6–26) | 24 | SR: 76 | 49 | mTICI 2b–3: 85 | mRS 0–2: 53 | 6 |
Retrospective | CA: 18 | Mortality: 18 | |||||||
Angioplasty: 0 | |||||||||
Baek 2019 [45] | Single center | 53 | 12 (7–25) | 15.1 | SR: 73.3 | 45 | mTICI 2b–3: 84.9 | mRS 0–2: 41.5 | 1.9 |
Retrospective | CA: 20 | Mortality: 22.6 | |||||||
IA thrombolysis: 6.7 | |||||||||
Sun 2021 [49] | Single center | 43 | 26 (11–32) | 18.6 | SR: 95.3 | 60 | mTICI 2b–3: 95.3 | mRS 0–2: 44.2 | 4.7 |
Retrospective | Infusion tirofiban: 65.1 | mTICI 3: 79.1 | mRS 0–3: 51.2 | ||||||
Balloon angioplasty: 9.3 | Mortality: 16.3 | ||||||||
Stenting: 14 | |||||||||
Jiang 2021 [48] | Single center | 33 | 20.2±9.2 | 15 | SR: 85 | 70 | mTICI 2b–3: 97 | mRS 0–3: 55 | 3 |
Retrospective | CA: 12 | ||||||||
Kwon 2022 [43] | Single center | 36 | 13 (7–22) | 27.8 | SR: 66.7 | 36 | mTICI 2b–3: 97.2 | mRS 0–2: 33.3 | 3.1 |
Retrospective | CA: 50 | mTICI 3: 55.6 | Mortality: 19.4 | ||||||
Pirson 2022 [24] | MR CLEAN | 48 | 14 (7–20) | 31 | SR: 74 | 47 | NA | mRS 0–2: 44 | NA |
Retrospective | CA: 23 | ||||||||
Stenting: 2 |
Values are presented as median (interquartile range) or mean±standard deviation.
NIHSS, National Institutes of Health Stroke Scale; IV, intra-venous; tPA, tissue plasminogen activator; sICH, symptomatic intracranial hemorrhage; SR, stent retriever; CA, contact aspiration; mTICI, modified thrombolysis in cerebral infarction scale; mRS, modified Rankin scale; NA, not available; IA, intra-arterial; MR CLEAN, multicenter randomized clinical trial of endovascular treatment for acute ischemic stroke in the Netherlands.
Table 5.
First author year | Number | NIHSS, median | IV tPA (%) | Procedure time* (min) | Access route‡ (%) | Technique (%) | Angiographic outcome (%) | Clinical outcome† (%) | sICH (%) |
---|---|---|---|---|---|---|---|---|---|
Cohen 2016 [80] | 7 | 22 | 14.3 | 68 | Dirty-road: 71.4 | SR: 100 | mTICI 2b–3: 100 | mRS 0–2: 28.6 | 14.3 |
Clean-road: 28.6 | mTICI 3: 85.7 | ||||||||
Siebert 2019 [56] | 38 | 18 | 28.9 | 91 | Dirty-road: 77.4 | SR: 84.2 | mTICI 2b–3: 86.8 | mRS 0–2: 15.8 | 2.6 |
Clean-road: 22.5 | CA: 15.8 | Mortality: 39.5 | |||||||
Angioplasty: 52.6 | |||||||||
Baik 2019 [23] | 28 | 18 | 21 | 66 | Dirty-road: 57 | SR: 54 | mTICI 2b–3: 86 | mRS 0–2: 29 | 4 |
Clean-road: 43 | CA: 36 | ||||||||
Angioplasty: 29 | |||||||||
Piechowiak 2020 [44] | 15 | 23 | 46.7 | 57 | Dirty-road: 73.3 | Angioplasty: 53.3 | mTICI 2b–3: 100 | mRS 0–2: 53.3 | 0 |
Clean-road: 26.7 | Mortality: 20 | ||||||||
Baik 2020 [83] | 55 | 20 | 25.5 | 61 | Dirty-road: 60.0 | SR: 67.3 | mTICI 2b–3: 87.2 | mRS 0–2: 30.9 | 5.5 |
Clean-road: 40.0 | CA: 21.8 | mTICI 3: 56.4 | Mortality: 21.8 | ||||||
Angioplasty: 29.1 | |||||||||
Xing 2020 [81] | 21 | 28 | 19 | 76 | Dirty-road: 38.1 | Angioplasty: 57.1 | mTICI 2b–3: 100 | mRS 0–3: 57.1 | 4.8 |
Clean-road: 61.9 | mTICI 3: 95.2 | mRS 0–2: 52.4 | |||||||
Elhorany 2020 [82] | 15 | 22 | 46.7 | 103 | Dirty-road: 73.3 | Angioplasty: 7 | mTICI 2b–3: 73.3 | mRS 0–2: 26.7 | 13.3 |
Clean-road: 26.7 | Mortality: 46.7 | ||||||||
Sun 2021 [49] | 23 | 29 | 17.4 | 108 | Dirty-road: 82.6 | Angioplasty: 78.3 | mTICI 2b–3: 60.9 | mRS 0–2: 26.1 | 13 |
Clean-road: 17.4 | mTICI 3: 52.2 | mRS 0–3: 30.4 | |||||||
Mortality: 47.8 | |||||||||
Jiang 2021 [48] | 17 | 14 | 12 | 127 | NA | SR: 53 | mTICI 2b–3: 94 | mRS 0–3: 88 | 6 |
CA: 18 | Mortality: 12 | ||||||||
Angioplasty: 30 | |||||||||
Kwon 2022 [43] | 16 | 10 | 18.8 | 62 | NA | SR: 68.8 | mTICI 2b–3: 87.5 | mRS 0–2: 43.8 | 0 |
CA: 37.6 | mTICI 3: 56.3 | Mortality: 6.3 | |||||||
Angioplasty: 68.8 |